We are focused on developing and commercializing drugs that treat very serious lung infections in orphan disease populations.
Our lead product candidate, ARIKAYCE, has multiple clinical and patient benefits.
Proprietary inhaled liposomal formulation of the antibiotic amikacin, an FDA-approved aminoglycoside that is currently delivered intravenously
Engineered to deliver amikacin directly to the site of serious lung infections
Potential for improvements to the conventional inhalation methods of delivering drug to the pulmonary system
We have two near-term commercial opportunities in orphan lung diseases.
Europe: ARIKAYCE Phase 3 trial to treat CF patients with Pseudomonas lung infections enrollment completed. Top line data reported in July, 2013.
US: ARIKAYCE Phase 2 trial to treat NTM enrollment well underway. Potential accelerated path to approval
We have near-term value-driving milestones.
Phase 3 CF-related Pseudomonas lung infection data reported in July, 2013.
Phase 2b NTM lung infection data expected by Q1 2014
We have a solid and broad IP portfolio.
More than a decade of investment in research and development
Potential coverage into 2029
We are well-capitalized and are building out our infrastructure.
$81.6 million in cash (as of March 31, 2013)
Mar 6, 2014
Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
Feb 19, 2014
Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
Feb 12, 2014
Insmed to present at Leerink Global Healthcare Conference at the Waldorf Astoria, NYC
Listen to webcast
Nov 5, 2013
Insmed to Host Third Quarter 2013 Financial
Listen to webcast
Key Clinical Publications
Insmed actively publishes and presents clinical data for ARIKAYCE.
Want to stay up to date on our news, events, and filings?
Set up your email alerts. Learn More
Investor & Media Contacts
Anne Marie Fields
Senior Vice President
Phone: (212) 838-3777
Phone: (310) 691-7100